8 Grants
2022
Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy.
Hao, Chunhai C and Hamdouchi, Chafiq
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) (ID: 1R01NS126358-01), $474,563USD, 2022-03-01 -- 2027-02-28
 
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer
Bellail, Anita⋅Hao, Chunhai C and Hamdouchi, Chafiq
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R44CA265547-01A1), $1,019,583USD, 2022-07-01 -- 2024-06-30
2021
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203893-06), $361,051USD, 2016-12-15 -- 2021-11-30
2020
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203893-05), $341,646USD, 2016-12-15 -- 2021-11-30
2019
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203893-04), $367,808USD, 12/15/2016 -- 11/30/2021
2018
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA203893-02), $316,675USD, 12/15/2016 -- 11/30/2021
 
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA203893-03), $378,761USD, 12/15/2016 -- 11/30/2021
2017
SUMO1 inhibition compound as a new anticancer drug for glioblastoma therapy
Hao, Chunhai C
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA203893-01A1), $359,147USD, 12/15/2016 -- 11/30/2021